Schering’s commitment to biotechnology in the early 1990s was a landmark decision for the company, says Dr. Guiseppe Vita, who is stepping down as chairman of the Berlin-based company. The result of that commitment was Betaferon (interferon beta-Ib), one of the first biotech products on the market in Germany. It is now Schering’s biggest product and one of the top ten best selling biotech therapies in the world.
